Therapeutic angiogenesis for revascularization in peripheral artery disease

Gene

Volumn 525, Issue 2, 2013, Pages 220-228

  Grochot Przeczek, Anna ^a   Dulak, Jozef ^a   Jozkowicz, Alicja ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Cell therapy; Gene therapy; Heme oxygenase 1; Limb ischemia; Peripheral artery disease; Therapeutic angiogenesis

Indexed keywords

ANGIOPOIETIN 1; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEME OXYGENASE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR; RECOMBINANT SCATTER FACTOR; RECOMBINANT VASCULOTROPIN;

ANGIOGENESIS; ANGIOMA; ANTIOXIDANT ACTIVITY; ARTICLE; BONE MARROW TRANSPLANTATION; CELL THERAPY; CLINICAL TRIAL (TOPIC); EDEMA; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; HUMAN; IMMUNOMODULATION; LIMB ISCHEMIA; NEPHROTOXICITY; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVASCULARIZATION;

ACIDIC FIBROBLAST GROWTH FACTOR; ADENOVIRAL VECTOR ENCODING VASCULAR ENDOTHELIAL GROWTH FACTOR; ADVEGF; AFGF; ANG-1; ANGIOPOIETIN 1; BASIC FIBROBLAST GROWTH FACTOR; BFGF; BILIVERDIN REDUCTASE; BMDCS; BONE MARROW-DERIVED CELLS; BVR; CELL THERAPY; DEL-1; DEVELOPMENTAL ENDOTHELIAL LOCUS-1; ENDOTHELIAL PROGENITOR CELLS; EPCS; G-CSF; GENE THERAPY; GLUTATHIONE PEROXIDASE 1; GM-CSF; GPX-1; GRANULOCYTE MONOCYTE-COLONY STIMULATING FACTOR; GRANULOCYTE-COLONY STIMULATING FACTOR; HEME OXYGENASE-1; HEPATOCYTE GROWTH FACTOR; HGF; HIF-1Α; HO-1; HYPOXIA INDUCIBLE FACTOR-1Α; IL-1Β; IL-10; IL-6; INTERLEUKIN 1; INTERLEUKIN 1Β; INTERLEUKIN 6; LIMB ISCHEMIA; MANGANESE SUPEROXIDE DISMUTASE; MCP-1; MESENCHYMAL STEM CELLS; MNSOD; MONOCYTE CHEMOTACTIC PROTEIN-1; MSCS; PAD; PBDCS; PDGF; PERIPHERAL ARTERY DISEASE; PERIPHERAL BLOOD-DERIVED CELLS; PLACENTAL GROWTH FACTOR; PLATELET-DERIVED GROWTH FACTOR; PLGF; SDF-1; SNPP; STROMAL CELL-DERIVED FACTOR-1; THERAPEUTIC ANGIOGENESIS; TIN PROTOPORPHYRIN; TNFΑ; TUMOR NECROSIS FACTOR Α; VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2; VEGF; VEGF-R1; VEGF-R2; VON WILLEBRAND FACTOR; VWF;

ANIMALS; CLINICAL TRIALS AS TOPIC; GENETIC THERAPY; HEME OXYGENASE-1; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; PERIPHERAL ARTERIAL DISEASE; TISSUE THERAPY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84879886685     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.03.097     Document Type: Article

References (143)

1. Aizawa T., et al. Balloon injury does not induce heme oxygenase-1 expression, but administration of hemin inhibits neointimal formation in balloon-injured rat carotid artery. Biochem. Biophys. Res. Commun. 1999, 261:302-307.
2. Asahara T., et al. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 1995, 92:II365-II371.
3. Asahara T., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275:964-967.
4. Asahara T., et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ. Res. 1999, 85:221-228.
5. Badorff C., et al. Transdifferentiation of blood-derived human adult endothelial progenitor cells into functionally active cardiomyocytes. Circulation 2003, 107:1024-1032.
6. Baffour R., et al. Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant basic fibroblast growth factor in a rabbit model of acute lower limb ischemia: dose-response effect of basic fibroblast growth factor. J. Vasc. Surg. 1992, 16:181-191.
7. Baffour R., et al. Angiogenic therapy for the chronically ischemic lower limb in a rabbit model. J. Surg. Res. 2000, 93:219-229. 10.1006/jsre.2000.5980.
8. Bartsch T., et al. Transplantation of autologous mononuclear bone marrow stem cells in patients with peripheral arterial disease (the TAM-PAD study). Clin. Res. Cardiol. 2007, 96:891-899. 10.1007/s00392-007-0569-x.
9. Baumgartner I., et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998, 97:1114-1123.
10. Bauters C., et al. Site-specific therapeutic angiogenesis after systemic administration of vascular endothelial growth factor. J. Vasc. Surg. 1995, 21:314-324. (discussion 324-315).
11. Behrendt D., Ganz P. Endothelial function. From vascular biology to clinical applications. Am. J. Cardiol. 2002, 90:40L-48L.
12. Brouard S., et al. Carbon monoxide generated by heme oxygenase 1 suppresses endothelial cell apoptosis. J. Exp. Med. 2000, 192:1015-1026.
13. Brune B., Ullrich V. Inhibition of platelet aggregation by carbon monoxide is mediated by activation of guanylate cyclase. Mol. Pharmacol. 1987, 32:497-504.
14. Brunt K.R., et al. Ex Vivo Akt/HO-1 gene therapy to human endothelial progenitor cells enhances myocardial infarction recovery. Cell Transplant. 2012, 10.3727/096368912X653002.
15. Burt R.K., et al. Autologous peripheral blood CD133+ cell implantation for limb salvage in patients with critical limb ischemia. Bone Marrow Transplant. 2010, 45:111-116. 10.1038/bmt.2009.102.
16. Bush R.L., et al. Regulation of new blood vessel growth into ischemic skeletal muscle. J. Vasc. Surg. 1998, 28:919-928.
17. Chae J.K., et al. Coadministration of angiopoietin-1 and vascular endothelial growth factor enhances collateral vascularization. Arterioscler. Thromb. Vasc. Biol. 2000, 20:2573-2578.
18. Chen S.L., et al. Improvement of cardiac function after transplantation of autologous bone marrow mesenchymal stem cells in patients with acute myocardial infarction. Chin. Med. J. (Engl.) 2004, 117:1443-1448.
19. Chleboun J.O., Martins R.N., Mitchell C.A., Chirila T.V. bFGF enhances the development of the collateral circulation after acute arterial occlusion. Biochem. Biophys. Res. Commun. 1992, 185:510-516.
20. Cisowski J., et al. Role of heme oxygenase-1 in hydrogen peroxide-induced VEGF synthesis: effect of HO-1 knockout. Biochem. Biophys. Res. Commun. 2005, 326:670-676.
21. Clark J.E., Foresti R., Green C.J., Motterlini R. Dynamics of haem oxygenase-1 expression and bilirubin production in cellular protection against oxidative stress. Biochem. J. 2000, 348(Pt 3):615-619.
22. Clark J.E., et al. Heme oxygenase-1-derived bilirubin ameliorates postischemic myocardial dysfunction. Am. J. Physiol. Heart Circ. Physiol. 2000, 278:H643-H651.
23. Cobellis G., et al. Long-term effects of repeated autologous transplantation of bone marrow cells in patients affected by peripheral arterial disease. Bone Marrow Transplant. 2008, 42:667-672. 10.1038/bmt.2008.228.
24. Cooper L.T., et al. Proteinuria in a placebo-controlled study of basic fibroblast growth factor for intermittent claudication. Vasc. Med. 2001, 6:235-239.
25. Cudmore M., et al. Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. Circulation 2007, 115:1789-1797.
26. Dernbach E., et al. Antioxidative stress-associated genes in circulating progenitor cells: evidence for enhanced resistance against oxidative stress. Blood 2004, 104:3591-3597.
27. Deshane J., Wright M., Agarwal A. Heme oxygenase-1 expression in disease states. Acta Biochim. Pol. 2005, 52:273-284.
28. Deshane J., et al. Stromal cell-derived factor 1 promotes angiogenesis via a heme oxygenase 1-dependent mechanism. J. Exp. Med. 2007, 204:605-618.
29. Dulak J., et al. Gene transfer of naked VEGF plasmid induces the formation of microvessels but not mature collaterals in ischemic limb muscles. Eur. Surg. 2002, 34:105-110.
30. Dulak J., et al. Heme oxygenase activity modulates vascular endothelial growth factor synthesis in vascular smooth muscle cells. Antioxid. Redox Signal. 2002, 4:229-240.
31. Emanueli C., et al. Local delivery of human tissue kallikrein gene accelerates spontaneous angiogenesis in mouse model of hindlimb ischemia. Circulation 2001, 103:125-132.
32. Fadini G.P., Agostini C., Avogaro A. Autologous stem cell therapy for peripheral arterial disease meta-analysis and systematic review of the literature. Atherosclerosis 2010, 209:10-17. 10.1016/j.atherosclerosis.2009.08.033.
33. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin. Oncol. 2002, 29:10-14. 10.1053/sonc.2002.37264.
34. Freitas A., et al. Heme oxygenase/carbon monoxide-biliverdin pathway down regulates neutrophil rolling, adhesion and migration in acute inflammation. Br. J. Pharmacol. 2006, 149:345-354.
35. Galasso G., et al. Impaired angiogenesis in glutathione peroxidase-1-deficient mice is associated with endothelial progenitor cell dysfunction. Circ. Res. 2006, 98:254-261.
36. Gowdak L.H., et al. Induction of angiogenesis by cationic lipid-mediated VEGF165 gene transfer in the rabbit ischemic hindlimb model. J. Vasc. Surg. 2000, 32:343-352. 10.1067/mva.2000.107566.
37. Grochot-Przeczek A., et al. Heme oxygenase-1 accelerates cutaneous wound healing in mice. PLoS One 2009, 4:e5803.
38. Grochot-Przeczek A., Dulak J., Jozkowicz A. Heme oxygenase-1 in neovascularisation: a diabetic perspective. Thromb. Haemost. 2010, 104:424-431.
39. Grossman P.M., et al. Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease. Am. Hear. J. 2007, 153:874-880. 10.1016/j.ahj.2007.01.038.
40. Hai-Jiang W., Xin-Na D., Hui-Jun D. Expansion of hematopoietic stem/progenitor cells. Am. J. Hematol. 2008, 83:922-926.
41. Hamano K., et al. Therapeutic angiogenesis induced by local autologous bone marrow cell implantation. Ann. Thorac. Surg. 2002, 73:1210-1215.
42. He T., et al. Human endothelial progenitor cells tolerate oxidative stress due to intrinsically high expression of manganese superoxide dismutase. Arterioscler. Thromb. Vasc. Biol. 2004, 24:2021-2027.
43. Hesheng O., et al. Role of endogenous carbon monoxide in neointimal formation induced by balloon-injury in rat aorta. Chin. Med. Sci. J. 1999, 14:41-45.
44. Huang J., et al. Sendai viral vector mediated angiopoietin-1 gene transfer for experimental ischemic limb disease. Angiogenesis 2009, 12:243-249. 10.1007/s10456-009-9144-6.
45. Idei N., et al. Autologous bone-marrow mononuclear cell implantation reduces long-term major amputation risk in patients with critical limb ischemia: a comparison of atherosclerotic peripheral arterial disease and Buerger disease. Circ. Cardiovasc. Interv. 2011, 4:15-25. 10.1161/CIRCINTERVENTIONS.110.955724.
46. Ishida A., et al. Autologous peripheral blood mononuclear cell implantation for patients with peripheral arterial disease improves limb ischemia. Circ. J. 2005, 69:1260-1265.
47. Ishikawa K., et al. Heme oxygenase-1 inhibits atherogenesis in Watanabe heritable hyperlipidemic rabbits. Circulation 2001, 104:1831-1836.
48. Ishikawa K., et al. Heme oxygenase-1 inhibits atherosclerotic lesion formation in ldl-receptor knockout mice. Circ. Res. 2001, 88:506-512.
49. Isner J.M., et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 1996, 348:370-374.
50. Isner J.M., et al. Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. J. Vasc. Surg. 1998, 28:964-973. (discussion 973-965).
51. Ito W.D., et al. Monocyte chemotactic protein-1 increases collateral and peripheral conductance after femoral artery occlusion. Circ. Res. 1997, 80:829-837.
52. Jazwa A., et al. Effect of heme and heme oxygenase-1 on vascular endothelial growth factor synthesis and angiogenic potency of human keratinocytes. Free Radic. Biol. Med. 2006, 40:1250-1263.
53. Jazwa A., et al. Pre-emptive hypoxia-regulated HO-1 gene therapy improves post-ischaemic limb perfusion and tissue regeneration in mice. Cardiovasc. Res. 2013, 97:115-124. 10.1093/cvr/cvs284.
54. Jiang Y.B., et al. Effects of heme oxygenase-1 gene modulated mesenchymal stem cells on vasculogenesis in ischemic swine hearts. Chin. Med. J. (Engl.) 2011, 124(401-407).
55. Jie K.E., Goossens M.H., van Oostrom O., Lilien M.R., Verhaar M.C. Circulating endothelial progenitor cell levels are higher during childhood than in adult life. Atherosclerosis 2009, 202:345-347.
56. Jozkowicz A., Dulak J. Effects of protoporphyrins on production of nitric oxide and expression of vascular endothelial growth factor in vascular smooth muscle cells and macrophages. Acta Biochim. Pol. 2003, 50:69-79.
57. Jozkowicz A., et al. Effect of prostaglandin-J(2) on VEGF synthesis depends on the induction of heme oxygenase-1. Antioxid. Redox Signal. 2002, 4:577-585.
58. Jozkowicz A., et al. Delivery of high dose VEGF plasmid using fibrin carrier does not influence its angiogenic potency. Int. J. Artif. Organs 2003, 26:161-169.
59. Jozkowicz A., et al. Heme oxygenase and angiogenic activity of endothelial cells: stimulation by carbon monoxide and inhibition by tin protoporphyrin-IX. Antioxid. Redox Signal. 2003, 5:155-162.
60. Jozkowicz A., et al. Opposite effects of prostaglandin-J2 on VEGF in normoxia and hypoxia: role of HIF-1. Biochem. Biophys. Res. Commun. 2004, 314:31-38.
61. Jozkowicz A., Was H., Dulak J. Heme oxygenase-1 in tumors: is it a false friend?. Antioxid. Redox Signal. 2007, 9:2099-2117.
62. Kalka C., et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:3422-3427.
63. Katsu M., et al. Ex vivo gene delivery of ephrin-B2 induces development of functional collateral vessels in a rabbit model of hind limb ischemia. J. Vasc. Surg. 2009, 49:192-198. 10.1016/j.jvs.2008.08.007.
64. Kawamoto A., et al. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation 2001, 103:634-637.
65. Kawamoto A., et al. Intramuscular transplantation of G-CSF-mobilized CD34(+) cells in patients with critical limb ischemia: a phase I/IIa, multicenter, single-blinded, dose-escalation clinical trial. Stem Cells 2009, 27:2857-2864.
66. Kim H.J., et al. Vascular endothelial growth factor-induced angiogenic gene therapy in patients with peripheral artery disease. Exp. Mol. Med. 2004, 36:336-344.
67. Kong D., et al. Enhanced inhibition of neointimal hyperplasia by genetically engineered endothelial progenitor cells. Circulation 2004, 109:1769-1775.
68. Koshikawa M., et al. Therapeutic angiogenesis by bone marrow implantation for critical hand ischemia in patients with peripheral arterial disease: a pilot study. Curr. Med. Res. Opin. 2006, 22:793-798. 10.1185/030079906X1000078.
69. Kreiser D., et al. Heme oxygenase-1 modulates fetal growth in the rat. Lab. Invest. 2002, 82:687-692.
70. Kusumanto Y.H., et al. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial. Hum. Gene Ther. 2006, 17:683-691. 10.1089/hum.2006.17.683.
71. Lara-Hernandez R., et al. Safety and efficacy of therapeutic angiogenesis as a novel treatment in patients with critical limb ischemia. Ann. Vasc. Surg. 2010, 24:287-294.
72. Lasala G.P., Silva J.A., Gardner P.A., Minguell J.J. Combination stem cell therapy for the treatment of severe limb ischemia: safety and efficacy analysis. Angiology 2010, 61:551-556. 10.1177/0003319710364213.
73. Lazarous D.F., et al. Effects of chronic systemic administration of basic fibroblast growth factor on collateral development in the canine heart. Circulation 1995, 91:145-153.
74. Lazarous D.F., et al. Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury. Circulation 1996, 94:1074-1082.
75. Lazarous D.F., et al. Basic fibroblast growth factor in patients with intermittent claudication: results of a phase I trial. J. Am. Coll. Cardiol. 2000, 36:1239-1244.
76. Lederman R.J., et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 2002, 359:2053-2058.
77. Lee J.S., et al. Combined administration of naked DNA vectors encoding VEGF and bFGF enhances tissue perfusion and arteriogenesis in ischemic hindlimb. Biochem. Biophys. Res. Commun. 2007, 360:752-758. 10.1016/j.bbrc.2007.06.120.
78. Lenk K., et al. Therapeutical potential of blood-derived progenitor cells in patients with peripheral arterial occlusive disease and critical limb ischaemia. Eur. Heart J. 2005, 26:1903-1909. 10.1093/eurheartj/ehi285.
79. Li Volti G., et al. Carbon monoxide signaling in promoting angiogenesis in human microvessel endothelial cells. Antioxid. Redox Signal. 2005, 7:704-710.
80. Lin Q., et al. Heme oxygenase-1 protein localizes to the nucleus and activates transcription factors important in oxidative stress. J. Biol. Chem. 2007, 282:20621-20633.
81. Luttun A., et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat. Med. 2002, 8:831-840. 10.1038/nm731.
82. Mack C.A., et al. Salvage angiogenesis induced by adenovirus-mediated gene transfer of vascular endothelial growth factor protects against ischemic vascular occlusion. J. Vasc. Surg. 1998, 27:699-709.
83. Maines M.D., Kappas A. Enzymatic oxidation of cobalt protoporphyrin IX: observations on the mechanism of heme oxygenase action. Biochemistry 1977, 16:419-423.
84. Maines M.D., Trakshel G.M., Kutty R.K. Characterization of two constitutive forms of rat liver microsomal heme oxygenase. Only one molecular species of the enzyme is inducible. J. Biol. Chem. 1986, 261:411-419.
85. Makinen K., et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Mol. Ther. 2002, 6:127-133. 10.1006/mthe.2002.0638.
86. Martins R.N., Chleboun J.O., Sellers P., Sleigh M., Muir J. The role of PDGF-BB on the development of the collateral circulation after acute arterial occlusion. Growth Factors 1994, 10:299-306.
87. Massa M., et al. Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. Blood 2005, 105:199-206.
88. Morishita R., et al. Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy. Hypertension 1999, 33:1379-1384.
89. Motukuru V., Suresh K.R., Vivekanand V., Raj S., Girija K.R. Therapeutic angiogenesis in Buerger's disease (thromboangiitis obliterans) patients with critical limb ischemia by autologous transplantation of bone marrow mononuclear cells. J. Vasc. Surg. 2008, 48:53S-60S. (discussion 60S). 10.1016/j.jvs.2008.09.005.
90. Murohara T., et al. Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization. J. Clin. Invest. 2000, 105:1527-1536.
91. Norgren L., et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J. Vasc. Surg. 2007, 45(Suppl. S):S5-S67. 10.1016/j.jvs.2006.12.037.
92. Ohara N., et al. Adenovirus-mediated ex vivo gene transfer of basic fibroblast growth factor promotes collateral development in a rabbit model of hind limb ischemia. Gene Ther. 2001, 8:837-845. 10.1038/sj.gt.3301475.
93. Ollinger R., et al. Bilirubin: a natural inhibitor of vascular smooth muscle cell proliferation. Circulation 2005, 112:1030-1039.
94. Pearson J.D. Endothelial progenitor cells-an evolving story. Microvasc. Res. 2010, 79:162-168. 10.1016/j.mvr.2009.12.004.
95. Powell R.J., et al. Interim analysis results from the RESTORE-CLI, a randomized, double-blind multicenter phase II trial comparing expanded autologous bone marrow-derived tissue repair cells and placebo in patients with critical limb ischemia. J. Vasc. Surg. 2011, 54:1032-1041. 10.1016/j.jvs.2011.04.006.
96. Prokopi M., et al. Proteomic analysis reveals presence of platelet microparticles in endothelial progenitor cell cultures. Blood 2009, 114:723-732. 10.1182/blood-2009-02-205930.
97. Pu L.Q., et al. Enhanced revascularization of the ischemic limb by angiogenic therapy. Circulation 1993, 88:208-215.
98. Pu L.Q., et al. Enhanced revascularisation after angiogenic stimulation in a rabbit model of bilateral limb ischaemia. Eur. J. Vasc. Endovasc. Surg. 1995, 9:189-196.
99. Radhakrishnan N., et al. Human heme oxygenase-1 deficiency presenting with hemolysis, nephritis, and asplenia. J. Pediatr. Hematol. Oncol. 2011, 33:74-78.
100. Rajagopalan S., et al. Regional Angiogenesis with Vascular Endothelial Growth Factor (VEGF) in peripheral arterial disease: design of the RAVE trial. Am. Hear. J. 2003, 145:1114-1118. 10.1016/S0002-8703(03)00102-9.
101. Rehman J., Li J., Orschell C.M., March K.L. Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 2003, 107:1164-1169.
102. Rivard A., et al. Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am. J. Pathol. 1999, 154:355-363. 10.1016/S0002-9440(10)65282-0.
103. Rohde E., et al. Blood monocytes mimic endothelial progenitor cells. Stem Cells 2006, 24:357-367. 10.1634/stemcells.2005-0072.
104. Rosengart T.K., et al. Therapeutic angiogenesis: a comparative study of the angiogenic potential of acidic fibroblast growth factor and heparin. J. Vasc. Surg. 1997, 26:302-312.
105. Saigawa T., et al. Clinical application of bone marrow implantation in patients with arteriosclerosis obliterans, and the association between efficacy and the number of implanted bone marrow cells. Circ. J. 2004, 68:1189-1193.
106. Schatteman G.C., Hanlon H.D., Jiao C., Dodds S.G., Christy B.A. Blood-derived angioblasts accelerate blood-flow restoration in diabetic mice. J. Clin. Invest. 2000, 106:571-578.
107. Sekiguchi H., Ii M., Losordo D.W. The relative potency and safety of endothelial progenitor cells and unselected mononuclear cells for recovery from myocardial infarction and ischemia. J. Cell. Physiol. 2009, 219:235-242.
108. Shi Q., et al. Proof of fallout endothelialization of impervious Dacron grafts in the aorta and inferior vena cava of the dog. J. Vasc. Surg. 1994, 20:546-556. (discussion 556-547).
109. Shi Q., et al. Evidence for circulating bone marrow-derived endothelial cells. Blood 1998, 92:362-367.
110. Shyu K.G., Manor O., Magner M., Yancopoulos G.D., Isner J.M. Direct intramuscular injection of plasmid DNA encoding angiopoietin-1 but not angiopoietin-2 augments revascularization in the rabbit ischemic hindlimb. Circulation 1998, 98:2081-2087.
111. Shyu K.G., Chang H., Wang B.W., Kuan P. Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical leg ischemia. Am. J. Med. 2003, 114:85-92.
112. Stark J., et al. Basic fibroblast growth factor stimulates angiogenesis in the hindlimb of hyperglycemic rats. J. Surg. Res. 1998, 79:8-12. 10.1006/jsre.1998.5392.
113. Stump M.M., Jordan G.L., Debakey M.E., Halpert B. Endothelium grown from circulating blood on isolated intravascular Dacron hub. Am. J. Pathol. 1963, 43:361-367.
114. Suh W., et al. Transplantation of endothelial progenitor cells accelerates dermal wound healing with increased recruitment of monocytes/macrophages and neovascularization. Stem Cells 2005, 23:1571-1578. 10.1634/stemcells.2004-0340.
115. Suzuki M., et al. Facilitated angiogenesis induced by heme oxygenase-1 gene transfer in a rat model of hindlimb ischemia. Biochem. Biophys. Res. Commun. 2003, 302:138-143.
116. Tabata H., Silver M., Isner J.M. Arterial gene transfer of acidic fibroblast growth factor for therapeutic angiogenesis in vivo: critical role of secretion signal in use of naked DNA. Cardiovasc. Res. 1997, 35:470-479.
117. Taha H., et al. Role of heme oxygenase-1 in human endothelial cells: lesson from the promoter allelic variants. Arterioscler. Thromb. Vasc. Biol. 2010, 30:1634-1641.
118. Takahashi T., et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat. Med. 1999, 5:434-438. 10.1038/7434.
119. Takeshita S., et al. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J. Clin. Invest. 1994, 93:662-670. 10.1172/JCI117018.
120. Takeshita S., et al. Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia. Circulation 1994, 90:II228-II234.
121. Takeshita S., et al. Gene transfer of naked DNA encoding for three isoforms of vascular endothelial growth factor stimulates collateral development in vivo. Lab. Invest. 1996, 75:487-501.
122. Takeshita S., et al. Therapeutic angiogenesis following arterial gene transfer of vascular endothelial growth factor in a rabbit model of hindlimb ischemia. Biochem. Biophys. Res. Commun. 1996, 227:628-635. 10.1006/bbrc.1996.1556.
123. Takeshita S., et al. Endothelium-dependent relaxation of collateral microvessels after intramuscular gene transfer of vascular endothelial growth factor in a rat model of hindlimb ischemia. Circulation 1998, 98:1261-1263.
124. Tang Y.L., et al. Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector. J. Am. Coll. Cardiol. 2005, 46:1339-1350.
125. Tateishi-Yuyama E., et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 2002, 360:427-435.
126. Thorup C., Jones C.L., Gross S.S., Moore L.C., Goligorsky M.S. Carbon monoxide induces vasodilation and nitric oxide release but suppresses endothelial NOS. Am. J. Physiol. 1999, 277:F882-F889.
127. Thum T., et al. Age-dependent impairment of endothelial progenitor cells is corrected by growth-hormone-mediated increase of insulin-like growth-factor-1. Circ. Res. 2007, 100:434-443.
128. Tsubokawa T., et al. Impact of anti-apoptotic and anti-oxidative effects of bone marrow mesenchymal stem cells with transient overexpression of heme oxygenase-1 on myocardial ischemia. Am. J. Physiol. Heart Circ. Physiol. 2010, 298:H1320-H1329. 10.1152/ajpheart.01330.2008.
129. Tsurumi Y., et al. Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation 1996, 94:3281-3290.
130. Vajanto I., et al. Evaluation of angiogenesis and side effects in ischemic rabbit hindlimbs after intramuscular injection of adenoviral vectors encoding VEGF and LacZ. J. Gene Med. 2002, 4:371-380. 10.1002/jgm.287.
131. Vincent K.A., et al. Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1alpha/VP16 hybrid transcription factor. Circulation 2000, 102:2255-2261.
132. Wagner M., et al. Heme oxygenase-1 attenuates ischemia/reperfusion-induced apoptosis and improves survival in rat renal allografts. Kidney Int. 2003, 63:1564-1573.
133. Walder C.E., et al. Vascular endothelial growth factor augments muscle blood flow and function in a rabbit model of chronic hindlimb ischemia. J. Cardiovasc. Pharmacol. 1996, 27:91-98.
134. Walter D.H., et al. Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: a randomized-start, placebo-controlled pilot trial (PROVASA). Circ. Cardiovasc. Interv. 2011, 4:26-37. 10.1161/CIRCINTERVENTIONS.110.958348.
135. Witzenbichler B., et al. Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. Am. J. Pathol. 1998, 153:381-394. 10.1016/S0002-9440(10)65582-4.
136. Wojakowski W., et al. Effects of intracoronary delivery of allogenic bone marrow-derived stem cells expressing heme oxygenase-1 on myocardial reperfusion injury. Thromb. Haemost. 2012, 108:464-475. 10.1160/TH12-05-0303.
137. Yachie A., et al. Oxidative stress causes enhanced endothelial cell injury in human heme oxygenase-1 deficiency. J. Clin. Invest. 1999, 103:129-135.
138. Yang H.T., Feng Y. bFGF increases collateral blood flow in aged rats with femoral artery ligation. Am. J. Physiol. Heart Circ. Physiol. 2000, 278:H85-H93.
139. Yang H.T., Deschenes M.R., Ogilvie R.W., Terjung R.L. Basic fibroblast growth factor increases collateral blood flow in rats with femoral arterial ligation. Circ. Res. 1996, 79:62-69.
140. Yang H.T., Feng Y., Allen L.A., Protter A., Terjung R.L. Efficacy and specificity of bFGF increased collateral flow in experimental peripheral arterial insufficiency. Am. J. Physiol. Heart Circ. Physiol. 2000, 278:H1966-H1973.
141. Yang J.J., et al. Transplantation of adipose tissue-derived stem cells overexpressing heme oxygenase-1 improves functions and remodeling of infarcted myocardium in rabbits. Tohoku J. Exp. Med. 2012, 226:231-241.
142. Yla-Herttuala S., Markkanen J.E., Rissanen T.T. Gene therapy for ischemic cardiovascular diseases: some lessons learned from the first clinical trials. Trends Cardiovasc. Med. 2004, 14:295-300. 10.1016/j.tcm.2004.09.001.
143. Zeng B., et al. Effects of combined mesenchymal stem cells and heme oxygenase-1 therapy on cardiac performance. Eur. J. Cardiothorac. Surg. 2008, 34:850-856. 10.1016/j.ejcts.2008.05.049.